Clinical trials located in

Erlangen

Erlangen city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Erlangen, nestled in Bavaria, Germany, is renowned for its rich history and vibrant culture. Founded in the Middle Ages, it became a hub for Huguenot refugees in the 17th century, shaping its unique character. Home to the Friedrich-Alexander-University, one of Germany’s oldest universities, Erlangen is a blend of academic spirit and youthful energy. The city is also famous for its Bergkirchweih, an annual beer festival that rivals Oktoberfest in its fervor. With a blend of historical architecture and modern research institutes, Erlangen stands as a testament to Germany’s ability to merge the past with the future.

  • CT-EU-00117111

    Study assessing the effectiveness of Tebentafusp administered alone and in combination with Pembrolizumab in the treatment of advanced melanoma

    The aim of this study is to test new treatments for people with advanced skin melanoma that does not respond well to other therapies. The main focus was on a new experimental drug called tebentafusp, which is a special type of protein that helps the body’s immune system recognize and attack cancer cells.

    The study divided patients into three different groups. One group will receive tebentafusp alone. Another group will receive tebentafusp in combination with another immunotherapy drug called pembrolizumab. The third group will receive the treatment that the doctor thinks is best for the patient – this could be another experimental drug, standard therapy, or simply supportive care.

    Scientists are primarily focusing on the effectiveness of these treatments in shrinking tumors and extending patient survival. They will also monitor closely for any side effects to make sure the treatment is safe. The study is expected to last about two years and will include frequent check-ins to monitor patient responses.

    • Tebentafusp
    • Pembrolizumab
  • Study of asciminib dosing and safety in pediatric patients with Chronic Myeloid Leukemia

    This study is designed to determine the appropriate dosing and assess the safety of the drug asciminib for children and teenagers who have a specific type of leukemia called Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML-CP). These patients have previously been treated with at least one other medication known as a tyrosine kinase inhibitor (TKI). The study involves giving different doses of asciminib to see how well the drug works and how safe it is in young patients. The study will enroll participants into two age groups and will follow them over a five-year period to observe the effects of the treatment.

    • Asciminib
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Study on Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

    Patients with Primary Biliary Cholangitis (PBC) can participate in a clinical trial involving the drug Seladelpar, available in 5 mg and 10 mg capsule forms. The trial aims to evaluate the long-term safety and tolerability of this drug, also known by the code MBX-8025.

    Seladelpar is being tested on a group of approximately 500 patients to determine its long-term tolerability and effectiveness in individuals with PBC. The objective is also to assess the drug’s impact on patient-reported symptoms, such as itching (pruritus).

    The study includes individuals who have previously participated in PBC studies involving seladelpar. Participants will be monitored for 60 months to collect data on potential side effects and laboratory test results.

    The overall goal of the study is to improve the treatment of patients with Primary Biliary Cholangitis by thoroughly investigating the new drug in terms of its safety and efficacy.

    • Seladelpar
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    • Gimeracil
    • Oteracil
    • Tegafur
    • Gemcitabine
    • Cisplatin
    • Rilvegostomig
    • Capecitabine
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    • XXB750
  • Comparing treatments for new Large B-cell lymphoma patients

    The trial aims to analyze and compare two drug treatments for people who have a large B-Cell Lymphoma, a kind of cancer that affects a certain type of white blood cells, and have not yet started their treatment. The first treatment is a combination of glofitamab, polatuzumab vedotin, and other common drugs used for this condition: rituximab, cyclophosphamide, doxorubicin, and prednisone. The second treatment is the same, but doesn’t include the glofitamab. The goal is to understand which treatment is more effective and safer for the patient.

    • Prednisone
    • Polatuzumab vedotin
    • Glofitamab
    • Doxorubicin
    • Cyclophosphamide
    • Rituximab
  • Exploring new cancer treatment for small cell lung cancer and neuroendocrine neoplasms

    The DAREON™-5 study is looking at how different amounts of a cancer drug called BI 764532 can help people with a specific type of lung cancer called small cell lung cancer, as well as other euroendocrine neoplasms. The goal is to find the right dose of BI 764532, which can be manageable for patients when taken by itself. BI 764532 is a special type of molecule that could potentially boost the body’s immune system to fight cancer. The individuals participating in the study will receive the drug through a vein and the treatment’s effectiveness will be monitored regularly until the end of the study.

    • BI 764532- new potential medication for small cell lung cancer and neuroendocrine carcinomas
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    • Vibostolimab
    • Pembrolizumab
  • Study of Tucatinib, Trastuzumab and Pertuzumab in the treatment of HER2+ metastatic breast cancer

    The study is aimed at patients with HER2-positive breast cancer whose disease has spread locally, i.e. close to where it started, and cannot be surgically removed, or has spread to other parts of the body. Treatment in this study includes a combination of drugs: tucatinib (also known as TUKYSA, ONT-380, ARRY-380), trastuzumab (Herceptin, Herceptin Hylecta), and pertuzumab (Perjeta). Some patients will receive a placebo instead of tucatinib.

    All patients will receive trastuzumab and pertuzumab, plus either tucatinib or placebo. Trastuzumab is administered intravenously (IV) or subcutaneously, and pertuzumab is administered intravenously. In some cases, trastuzumab and pertuzumab may be administered subcutaneously in combination.

    The aim of the study is to check whether tucatinib in combination with trastuzumab and pertuzumab works better than placebo. This will also check what side effects may occur while taking this drug combination. Side effects are any adverse effects a drug may have on the body in addition to treating the disease.

    The study includes patients who have already undergone 4-8 cycles of pre-treatment with trastuzumab, pertuzumab and taxane as first-line treatment for advanced breast cancer, and do not show disease progression after completion of this pre-therapy. Patients can have both positive and negative hormone receptor status.

    • Pertuzumab
    • Tucatinib
    • Trastuzumab
  • A clinical trial evaluating Tominersen in the treatment of early stages of Huntington’s disease

    This clinical trial is focused on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease, a genetic disorder characterized by the progressive loss of nerve cells in the brain.

    The aim of this study is to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses of this drug or a placebo directly into the spinal cord to reach the areas of the brain most affected by the disease. Participants’ health will be closely monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional well-being. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study provides an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    • Placebo
    • Tominersen
  • R-Pola-Glo therapy for aggressive B-cell lymphoma

    This clinical study tests a new treatment combination called R-Pola-Glo for elderly or medically unfit patients with untreated aggressive B-cell lymphoma. It involves the anti-CD20 antibody rituximab with polatuzumab vedotin and glofitamab, aiming to develop a less intense chemotherapy option. The trial, enrolling 80 participants, will assess the effectiveness and safety of this therapy, which could be crucial for those ineligible for standard treatment due to age or health.

    • Polatuzumab vedotin
    • Obinutuzumab
    • Glofitamab
    • Rituximab
  • Comparing Imlifidase with standard treatment in anti-glomerular basement membrane disease

    This clinical trial is testing a medication called Imlifidase in patients who have a serious disease called anti-GBM (Goodpasture syndrome). The researchers are doing this study to compare two groups: people who take Imlifidase along with the usual treatment, and people who only get the usual treatment. This typical treatment consists of plasma exchange (PLEX), Cyclophosphamide and glucocorticoids. This study will last for 2 years. Researchers will measure things like kidney function, levels of harmful anti-GBM antibodies, breathing symptoms, drug interaction and patients’ quality of life.

    • Cyclophosphamide (CYC)
    • Glucocorticoids
    • Imlifidase
  • Testing new treatment for rare genetic disorder X-linked hypohidrotic ectodermal dysplasia

    This research is about trying a new treatment for unborn boys who are known to have a disease called X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare condition that affects parts of the body such as sweat glands, teeth, and hair. The reason this happens is due to errors in a certain gene. This leads to various problems like not being able to sweat properly, missing teeth, and not having normal hair growth. The tested treatment, called ER004, is meant to replace a missing protein that’s caused by these errors. The aim is to prevent the disease in the babies. There will be a long observational period for the boys after birth, up to 5 years, where doctors will check if the treatment is safe and effective. This includes their ability to sweat, the development of teeth, and overall health. Doctors will also compare these signs with the ones of boys who did not get the treatment or from a previous study. The health of the mothers after delivery will also be checked.

    • ER004
  • Ponatinib treatment for children with various advanced cancers

    This trial focuses on a drug called ponatinib, that is being studied for the treatment of children (aged 1-18) with different harsh illnesses such as leukemias, lymphomas, and solid tumors. The researchers want to understand how safe the drug is, how well it works, and what happens to the drug in the body. Researchers will monitor any side effects that occur within the first 28 days of taking ponatinib. The researchers will also check if the drug is helping to reduce the illness by checking if there are fewer cancer cells in the body. The effects of the drug on the tumor will be monitored through scans like CT or MRI.

    • Ponatinib
  • Testing ustekinumab treatment for severe ulcerative colitis

    This clinical trial is focused on understanding the safety and effectiveness of a medication named Ustekinumab in children and adolescents who are experiencing moderate to severe Ulcerative Colitis (UC), a type of inflammatory bowel disease that causes long-lasting inflammation and ulcers in the digestive tract. The study administers Ustekinumab initially through an IV (intravenous infusion) and then as a subcutaneous injection. The main aims are to determine whether Ustekinumab can help these young patients achieve clinical remission, meaning their UC symptoms are reduced or completely go away, and to monitor how the drug behaves in their bodies. Throughout the trial, the health and safety of the participants are closely monitored.

    • Ustekinumab
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Study of new potential drug in breast cancer and solid tumors

    This study investigates LOXO-783 as a potential treatment for advanced breast cancer and various solid tumors with a specific genetic mutation (PIK3CA gene). The research explores the safety, side effects, and effectiveness of LOXO-783 when administered alone or in combination with other anticancer therapies. Participation in the study may last up to 36 months, with the potential for an extended duration if the disease does not progress. The aim is to gain valuable insights into the treatment of these cancers and improve our understanding of LOXO-783 in different therapeutic combinations.

    • Anastrozole
    • Letrozole
    • Exemestane
    • LOXO-783- new potential medication for solid tumors
    • Imlunestrant
    • Abemaciclib
    • Fulvestrant
    • Paclitaxel

See more clinical trials in other cities in Germany:

.